Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B
Authors:
Open Access
- 6 June 2014
- journal article
- clinical trial
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (6) , e98476
Abstract
About 350–400 million people are infected with hepatitis B virus (HBV) chronically and 1 million people die of hepatitis B virus (HBV)-related liver diseases. Nucleos(t)ide analogues (NAs) have been used for the treatment against HBV. However, few studies have investigated the long-term effects of different nucleos(t)ide analogues on levels of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB). The aims of this study were to measure the magnitude of HBsAg reduction by long-term monotherapy with adefovir dipivoxil (ADV) and entecavir (ETV), to compare HBsAg reduction between the two drugs of different potency and to predict the expected time needed to achieve HBsAg loss. We retrospectively evaluated the kinetics of HBsAg in 67 patients with CHB who all exhibited persistent viral suppression. These patients were treated with ADV or ETV for at least 6 years. HBV genotype was determined at baseline. Liver biochemistry, HBV serological markers, serum HBV DNA and HBsAg titers were determined at baseline, half year and yearly from year 1 to 6. Serum HBsAg titers after treatment with ADV or ETV were significantly lower than the baseline titers (P0.05). Serum HBsAg titers gradually decreased during long-term treatment with either ADV or ETV. It appears that the potency of ADV on HBsAg reduction is close to that of ETV, as long as patients have achieved persistent viral suppression.Keywords
This publication has 23 references indexed in Scilit:
- Reduction of Hepatitis B Surface Antigen Levels And Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients Receiving 10 Years of Nucleoside Analogue TherapyHepatology, 2013
- Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C InfectionPLOS ONE, 2013
- Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agentsJournal of Medical Virology, 2011
- Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavirHepatology, 2011
- Endpoints of therapy in chronic hepatitis B #Hepatology, 2009
- Monitoring during and after antiviral therapy for hepatitis B #Hepatology, 2009
- Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of “a” Determinant VariantsJournal of Virology, 2006
- New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNAJournal of Hepatology, 2005
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004
- Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapyHepatology, 1998